<DOC>
	<DOC>NCT00603499</DOC>
	<brief_summary>Objective : to test the BP lowering-effect of oral magnesium supplementation, as magnesium chloride (MgCl2) solution, 2.5 g daily, in uncomplicated hypertensive type 2 diabetic subjects with decreased serum magnesium levels Design : Randomised double blind placebo controlled trial. Setting : Outpatients with type 2 diabetes from Durango, city in northern Mexico Subjects : 82 subjects between 40 and 75 years of age with type 2 diabetes serum magnesium deficiency and uncomplicated hypertension. Interventions : During 4 months the intervention group received 2.5 gr of magnesium chloride (50 ml of a solution containing 50 gr of MgCl2 by 1000 ml of solution ). Controls received inert placebo. Main outcome measure: Change in blood pressure. Increase of serum magnesium Secondary outcomes measures: Changes in lipid profile</brief_summary>
	<brief_title>Magnesium and Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<criteria>Type 2 diabetes Decreased serum magnesium levels Uncomplicated hypertension 40 and 75 years of age Men and Women Chronic diarrhea Alcohol intake (equal or more than 30 g per day) Use of diuretics and/or calcium antagonists drugs Previous oral magnesium supplementation Ischemic diseases; AND Reduced renal function</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Hypomagnesemia</keyword>
</DOC>